1. 09.02 Bispecific antibodies enable synthetic agonistic receptor T cell therapy in melanoma. (21st September 2022) Authors: Benmebarek, M; Märkl, F; Keyl, J; Cadilha, B; Geiger, M; Karches, C; Obeck, H; Schwerdtfeger, M; Briukhovetska, D; Jobst, J; Müller, PJ; Seifert, M; Grünmeier, R; Thomas, M; Marr, C; Levesque, M; Heppt, M; Endres, S; Klein, C; Kobold, S Journal: Journal for immunotherapy of cancer Issue: Volume 10(2022)Supplement 1 Page Start: A4 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P065 Altered B cell expansion and maturation in Crohn's disease. (30th January 2023) Authors: Kappel-Latif, S; Kotagiri, P; Schuld, G; Schlager, L; Walterskirchen, N; Schimek, V; Jobst, J; Murthy, S; Messner, B; Lyons, P A; Oehler, R; Bergmann, M; Stift, A; Unger, L Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i233 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P09.03 Activation of IL-22 signaling correlates with higher CD155 expression and stratifies poor outcomes of early-stage lung and breast cancer patients. (21st September 2022) Authors: Briukhovetska, D; Jobst, J; Endres, S; Kobold, S Journal: Journal for immunotherapy of cancer Issue: Volume 10(2022)Supplement 1 Page Start: A33 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗